Pharmacologic treatment of obsessive-compulsive disorder: Which choice beyond serotonin re-uptake inhibitors?;Il trattamento farmacologico del disturbo ossessivo-compulsivo: Quali opzioni oltre gli inibitori del re-uptake della serotonina?

Italian Journal of Psychopathology

Volumn 13, Issue 2, 2007, Pages 209-221

  Maina, Giuseppe ^a   Pessina, E ^a   Asinari, G F ^a   Micari, J ^a   Bogetto, F ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Alternative agents; Obsessive compulsive disorder; Pharmacotherapy

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLORGYLINE; FLUOXETINE; FLUVOXAMINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; NICOTINE; NORTRIPTYLINE; ONDANSETRON; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; HUMAN; MEDLINE; MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 36549008730     PISSN: 15921107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Thorén P, Åsberg M, Cronholm B, Jörnestedt L, Träskman L. Clomipramine treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1980;37:1281-5.
2. March J, Frances A, Carpenter D, Kahn D. The Expert Consensus Guideline Series. Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(Suppl.4):1-64.
3. Bogetto F, Albert U, Maina G. Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol 2002;12:181-6.
4. Maina G, Albert U, Bogetto F. Relapses after discontinuation of drug associated with increased resistance to treatment in OCD. Int Clin Psychopharmacol 2001;16:33-8 .
5. Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry 2004;65:1365-71.
6. Montgomery SA. Clomipramine in obsessional neurosis: a placebo controlled trial. Pharm Med 1980;1:189.
7. Marks IM, Stern RS, Mawson D, Cobb J, McDonald R. Clomipramine and exposure for obsessive-compulsive rituals. Br J Psychiatry 1980;136:1-25.
8. Mavissakalian M, Turner SM, Michelson L, Jacob R. Tricyclic antidepressants in obsessive-compulsive disorder: Anti-obsessional or antidepressant agents? Am J Psychiatry 1985;142:572-6.
9. Snyder S. Amitriptyline therapy of obsessive-compulsive neurosis. J Clin Psychiatry 1980;41:286-9.
10. Ananth J, Pecknold JC, Van den Steen N, Engelsmann F. Double blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol 1981;5:257-62.
11. Zhao JP. A control study of clomipramine and amitriptyline for treating obsessive-compulsive disorder. Zhonghua Shen Jing Jing Shen Ke Za Zhi 1991;24:68-70.
12. Mavissakalian M, Michelson L. Tricyclic antidepressant in obsessive-compulsive disorder: antiobsessional or antidepressant agents? J Nerv Ment Dis 1983;171:301-6.
13. Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Res 1985;14:83-91.
14. Foa EB, Steketee G, Kozak MJ, Dugger D. Effects of imipramine on depression and obsessive-compulsive symptoms. Psychiatry Res 1987;21:123-36.
15. Foa EB, Kozak MJ, Steketee GS, McCarthy PR. Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behaviour therapy. Br J Clin Psychol 1992;31:279-92.
16. Joel SW. Twenty month study of iproniazid therapy. Dis Nerv Syst 1959;20:1-4.
17. Jain VK, Swinson RP, Thomas JG. Phenelzine in obsessional neurosis [letter]. Br J Psychiatry 1970;117:237-8.
18. Jenike MA, Surman OS, Cassem NH, Zusky P, Anderson WH. Monoamine oxidase inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1983;44:131-2.
19. Insel TR, Hamilton JA, Guttmacher LB, Murphy DL. D-amphetamine in obsessive-compulsive disorder. Psychopharmacol (Berl) 1983;80:231-5.
20. Vallejo J, Olivares J, Marcos T, Bulbena A, Menchon JM. Clomipramine versus phenelzine in obsessive-compulsive disorder: a controlled clinical trial. Br J Psychiatry 1992;161:665-70.
21. Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997;154:1261-4.
22. Prasad AJ. Obsessive-compulsive disorder and trazodone. Am J Psychiatry 1984;141:612-3.
23. Baxter LR. Two cases of obsessive-compulsive disorder with depression responsive to trazodone. J Nerv Ment Dis 1985;173:432-3.
24. Ramchandani D. Trazodone for bowel obsession. Am J Psychiatry 1990;147:124.
25. Prasad AJ. Efficacy of trazodone as an anti obsessional agent. Pharmacol Biochem Behav 1985;22:347-8.
26. Hermesh H, Aizenberg D, Munitz H. Trazodone treatment in clomipramine-resistant obsessive-compulsive disorder. Clin Neuropharmacol 1990;13:322-8.
27. Pigott TA, L'Hereux F, Rubenstein CS, Bernstein SE, Hill JL, Murphy DL. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:156-62.
28. Zajecka JM, Fawcett J, Guy C. Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine [letter]. J Clin Psychopharmacol 1990;10:152-3.
29. Ananth J, Burgoyne K, Smith M, Swartz R. Venlafaxine for treatment of obsessive-compulsive disorder [letter]. Am J Psychiatry 1995;152:1832.
30. Grossman R, Hollander E. Treatment of obsessive-compulsive disorder with venlafaxine [letter]. Am J Psychiatry 1996;153:576-7.
31. Rauch SL, O'Sullivan RL, Jenike MA. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases [letter]. J Clin Psychopharmacol 1996;153:576-7.
32. Albert U, Aguglia E, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 2002;63:1004-9.
33. Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Koran LM. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2003;64:546-50.
34. Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in obsessive-compulsive disorder [letter]. Arch Gen Psychiatry 1996;53:653-4.
35. Denys D, van der Wee N, van Megen HJGM, Westenberg HGM. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003;23:568-75.
36. Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. Evid Based Ment Health 2004;7:114.
37. Koran L, Quirk T, Loberbaum J, Elliott M. Mirtazapine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 2001;21:537-9.
38. Koran L, Gamel NN, Choung HW, Smith EH, Aboujaoude EN. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 2005;66:515-20.
39. Vulink NCC, Denys D, Westenberg HGM. Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed dose study. J Clin Psychiatry 2005;66:228-30.
40. Tesar GE, Jenike MA. Alprazolam as treatment for a case of obsessive-compulsive disorder. Am J Psychiatry 1984;141:689-90.
41. Ketter T, Chun D, Lu F. Alprazolam in the treatment of obsessive symptoms. J Clin Psychopharmacol 1986;6:59-60.
42. Tollefson G. Alprazolam in the treatment of obsessive symptoms. J Clin Psychopharmacol 1985;5:39-42.
43. Bodkin JA, White K. Clonazepam in the treatment of obsessive-compulsive disorder associated with panic disorder in one patient. J Clin Psychiatry 1989;50:265-6.
44. Bacher NH. Clonazepam treatment of obsessive-compulsive disorder. J Clin Psychiatry 1990;51:168-9.
45. Hewlett WA, Vinogradov S, Agras WS. Clonazepam treatment of obsessions and compulsions. J Clin Psychiatry 1990;51:158-61.
46. Ross DC, Pigott LR. Clonazepam for OCD (letter). J Am Acad Child Adoles Psychiatry 1993;32:470.
47. Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:420-30.
48. Hollander E, Kaplan A, Stahl SM. A double-blind, placebo controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry 2003;4:30-4.
49. Jenike MA, Baer L. An open trial of buspirone in obsessive-compulsive disorder. Am J Psychiatry 1988;145:1285-6.
50. Farid BT, Bulto M. Buspirone in obsessional compulsive disorder. A prospective case study. Pharmacopsychiatry 1994;27:207-9.
51. Pato MT, Pigott TA, Hill JL, Grover GN, Bernstein S, Murphy DL. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1991;148:127-9.
52. Trethowan WH, Scott PA. Chlorpromazine in obsessive-compulsive and allied disorders. Lancet 1955;268:781-5.
53. Altshuler M. Massive doses of trifluoperazine in the treatment of compulsive rituals. Am J Psychiatry 1962;119:367-8.
54. Hussain MZ, Ahad A. Treatment of obsessive-compulsive neurosis. Can Med Assoc J 1970;103:648.
55. O'Regan JB. Treatment of obsessive-compulsive neurosis with haloperidol. Can Med Assoc J 1970;103:167-8.
56. O'Regan JB. Treatment of obsessive-compulsive neurosis. Can Med Assoc J 1970;103:650-1.
57. Rivers-Burkeley N, Hollander MH. Successful treatment of obsessive-compulsive disorder with loxapine. Am J Psychiatry 1982;139:1345-6.
58. McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 1995;152:1812-4.
59. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JRT. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 2005;66:49-51.
60. Jenike MA, Brotman AW. The EEG in obsessive compulsive disorder. J Clin Psychiatry 1984;45:122-4.
61. Koopowitz LF, Berk M. Response of obsessive compulsive disorder to carbamazepine in two patients with comorbid epilepsy. Ann Clin Psychiatry 1997;9:171-3.
62. Khanna S. Carbamazepine in obsessive-compulsive disorder. Clin Neuropharmacol 1988;11:478-81.
63. Joffe RT, Swinson RP. Carbamazepine in obsessive-compulsive disorder. Biol Psychiatry 1987;22:1169-71.
64. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983;40:605-12.
65. Keuler DJ, Altemus M, Michelson D, Greenberg B, Murphy DL. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol Psychiatry 1996;40:154-6.
66. Goldsmith TD, Shapira NA, Keck PE. Rapid remission of OCD with tramadol hydrochloride. Am J Psychiatry 1999;156:660-1.
67. Shapira NA, Keck PE Jr, Goldsmith TD, McConville BJ, Eis M, McElroy SL. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety 1997;6:170-3.
68. Casas M, Alvarez E, Duro P, Garcia-Ribera C, Udina C, Velat A, et al. Antiandrogenic treatment of obsessive-compulsive neurosis. Acta Psychiatr Scand 1986;73:221-2.
69. Leonard HL. Drug treatment of obsessive-compulsive disorder. In: Rapaport JL, editor. Obsessive-compulsive disorder in children and adolescents. Washington, DC: American Psychiatric Press 1989, p. 217-36.
70. Weiss M, Baerg E, Wisebord S, Temple J. The influence of gonadal hormones on periodicity of obsessive-compulsive disorder. Can J Psychiatry 1995;40:205-7.
71. Chouinard G, Belanger MC, Beauclair L, Sultan S, Murphy BE. Potentiation of fluoxetine by aminoglutethimide; an adrenal steroid suppressant, in obsessive-compulsive disorder resistant to SSRIs: a case report. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:1067-79.
72. Altemus M, Greenberg BD, Keuler D, Jacobson KR, Murphy DL. Open trial of flutamide for treatment of obsessive-compulsive disorder. J Clin Psychiatry 1999;60:442-5.
73. Leckman JF, Goodman WK, North WC, Chappel PB, Price LH, Pauls DL, et al. Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder: comparison with Tourette's syndrome and healthy controls. Arch Gen Psychiatry 1994;51:782-92.
74. Ansseau M, Legros JJ, Mormont C, Cerfontaine JL, Papart P, Geenen V. Intranasal oxytocin in obsessive-compulsive disorder. Psychoneuroendocrinology 1987;12:231-6.
75. Salzberg AD, Swedo SE. Oxytocin e vasopressin in obsessive-compulsive disorder. Am J Psychiatry 1992;149:713-4.
76. Charles G, Guillaume R, Schittecatte M, Pholien P, Van Wettere JP, Wilmotte J. Oxytocin in the treatment of obsessive-compulsive disorder: a report on two cases. Psychiatry Psychobiol 1989;4:111-5.
77. Den Boer JA, Westenberg HG. Oxytocin in obsessive-compulsive disorder. Peptides 1992;13:1083-5.
78. Epperson CN, McDougle CJ, Price LH. Intranasal oxytocin in obsessive-compulsive disorder. Biol Psychiatry 1996;40:547-9.
79. Müller WE, Rolli E, Schäfer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997;30(Suppl.):102-7.
80. Rosenblatt JE, Rosenblatt NC, editors. Currents in affective disorders. Bethesda, MD: Currents Publications 1997.
81. Taylor LH, Kobak KA. An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000;61:575-8.
82. Kobak KA, Taylor LV, Bystritsky A, Kohlenberg CJ, Greist JH, Tucker P, et al. St. John's Wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol 2005;20:299-304.
83. Insel TR, Pickar D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am J Psychiatry 1983;140:1219-20.
84. Carlsson ML, Carlsson A. Use of a nicotine receptor agonist in the treatment of obsessive-compulsive disorder. 2000. Europe (EPC), Patent N. 1 126 186: New Zealand, Patent N. 511 226.
85. Lundberg S, Carlsson A, Norfeldt P, Carlsson ML. Nicotine treatment of obsessive-compulsive disorder. Prog Neuropharmacol Biol Psychiatry 2004;28:1195-9.
86. Salin-Pascual RJ, Basanez-Villa E. Changes in compulsion and anxiety symptoms with nicotine transdermal patches in non-smoking obsessive-compulsive disorder patients. Rev Invest Clin 2003;55:650-4.
87. 3 receptor antagonist, in the mouse elevated plus-maze. Pharmacol Biochem Behav 2001;69:571-88.
88. 3 receptor antagonist and its applications in CNS-related disorders. CNS Drug Reviews 2001;7:199-213.
89. Hewlett WA, Schmid SP, Salomon RM. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry 2003;64:1025-30.
90. Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, et al. Double-blind controlled trial of inositol treatment of depression. Am J Psychiatry 1995;152:792-4.
91. Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995;152:1084-6.
92. Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996;153:1219-21.
93. Carey PD, Warwick J, Harvey BH, Stein DJ, Seedat S. Single photon emission computed tomography (SPECT) in obsessive-compulsive disorder before and after treatment with inositol. Metab Brain Dis 2004;19:125-34.